Abstract

Protein Tyrosine kinase 6 (PTK6/BRK) is overexpressed in the majority of human breast tumors and breast tumor cell lines. It is also expressed in normal epithelial linings of the gastrointestinal tract, skin, and prostate. To date, expression of PTK6 has not been extensively examined in the normal human mammary gland. We detected PTK6 mRNA and protein expression in the immortalized normal MCF-10A human mammary gland epithelial cell line, and examined PTK6 expression and activation in a normal human breast tissue microarray, as well as in human breast tumors. Phosphorylation of tyrosine residue 342 in the PTK6 activation loop corresponds with its activation. Similar to findings in the prostate, we detect nuclear and cytoplasmic PTK6 in normal mammary gland epithelial cells, but no phosphorylation of tyrosine residue 342. However, in human breast tumors, striking PTK6 expression and phosphorylation of tyrosine 342 is observed at the plasma membrane. PTK6 is expressed in the normal human mammary gland, but does not appear to be active and may have kinase-independent functions that are distinct from its cancer promoting activities at the membrane. Understanding consequences of PTK6 activation at the plasma membrane may have implications for developing novel targeted therapies against this kinase.

Highlights

  • Protein tyrosine kinase 6 (PTK6, called BRK) is a SRC-related intracellular tyrosine kinase expressed in normal epithelia and cancer

  • PTK6 is expressed in breast cancer cell lines representing different molecular subtypes of breast cancer

  • We detected both PTK6 mRNA and protein expression in all of breast cancer cells lines that we examined, as well as in the nontransformed MCF-10A human mammary gland epithelial cell line (Figs. 1A, S1A-C)

Read more

Summary

Introduction

Protein tyrosine kinase 6 (PTK6, called BRK) is a SRC-related intracellular tyrosine kinase expressed in normal epithelia and cancer. PTK6 intracellular localization has been highlighted as an important regulator of its signaling in the prostate [6]. Targeting PTK6 into the nucleus of prostate cancer cells in vitro negatively regulates growth [8]. Targeting PTK6 to the plasma membrane by addition of a palmitoylation/myristoylation signal promoted the epithelial mesenchymal transition and enhanced growth and metastasis of prostate cancer www.impactjournals.com/oncotarget xenograft tumors [11]. Several studies have suggested that PTK6 is a potential therapeutic target in breast cancer. It promotes signaling by a number of receptor tyrosine kinases including members of the ERBB receptor family, MET, and IGF-1R (reviewed in [15, 16]). Transgene expression of PTK6 in the mouse mammary gland enhances mammary gland tumorigenesis in vivo [23, 24]

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.